CNP Options Flip Sharply as Shorts Trim Into Today's Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
CenterPoint Energy reports this morning with two of its most-watched signals pulling in opposite directions: short sellers cut positions over the past week while options traders made their biggest move toward downside protection in months.
The options shift is the sharper development. The put/call ratio jumped to 0.34 on Tuesday, 3.5 standard deviations above its 20-day average of 0.19. Four days earlier, the same ratio sat at 0.15, its lowest reading of the past year. That kind of reversal over four sessions, from the most call-heavy positioning on record to the highest put/call reading since September, reflects a rapid change of mind among options traders as the print arrived. The 52-week high on the PCR is 0.63, so the absolute level is not extreme, but the speed of the move is.
Short interest, meanwhile, has eased from its recent peak. The position was close to 49.5 million shares in mid-October. It has since retreated to 47.4 million, or 7.3% of the float, down about 2.6% on the session and 2.3% on the week. That pullback matters in context: previous articles noted the short position had climbed roughly 9% over the past month to reach a one-year high. The partial unwind suggests some of those bears covered ahead of the number rather than press into it. Borrowing conditions remain relaxed throughout, with availability at 497% of shares already borrowed and cost to borrow at 0.52%, confirming no squeeze mechanics are in play.
The analyst community is unusually active going into the release. TD Cowen and HSBC both initiated coverage with Buy ratings last week, setting targets of $47 and $44 respectively. Morgan Stanley raised its target a dollar to $39 while keeping its Equal-Weight rating. Those constructive moves sit alongside a wave of target cuts from earlier in the month: JP Morgan trimmed to $44 from $46, Barclays cut to $41 from $44, BMO lowered to $45 from $48, and Citigroup dropped to $43 from $47, all while maintaining their ratings. The mean analyst target is $44.16, about 5% above the current price of $41.97. The stock ranks in the 100th percentile for analyst recommendation divergence, meaning the spread of opinion across the Street is exceptionally wide. Bulls point to 8% weather-adjusted commercial and industrial sales growth year-to-date and an FFO-to-debt ratio within the company's 14% to 15% target range. Bears flag the planned Ohio gas utility sale, high interest rates and Texas political risk, with Moody's and S&P maintaining negative outlooks on the company's credit.
CNP gained 4.3% over the past week, outpacing its closest peers: WEC rose 2.5%, DTE gained 2.6%, ED 2.7%, and AEE 2.4%. That relative strength is notable given the stock spent much of 2026 lagging the regulated utility group. The only prior earnings reaction in the data, the July print, produced a 2.5% one-day decline followed by a 5.5% five-day drop. Wikipedia attention for the company is running at a z-score of 2.8 against its own 90-day history, well above normal levels, reflecting elevated retail interest into the release.
Today's print will test whether the recent operational momentum, particularly on the commercial and industrial load side, is robust enough to justify a stock now trading at a 14% premium to where it was a month ago, and whether management's guidance on the Ohio asset sale and balance sheet trajectory is sufficient to shift the negative credit outlooks.
Stocks in this article
See the live data behind this article on ORTEX.
Open CNP on ORTEX →How this article was generated
- Generated
- 28 Oct 2026, 04:09
- Data as of
- 28 Oct 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.